Ph1a/1b study of BBO-8520 in subjects with KRASG12C mutant NSCLC
Phase
Phase I Clinical Trial
Condition(s)
Lung Cancer
Trial Number
06343402
Trial Status
OPEN
Study Overview
TBBO8520-101: A Phase 1a/1b Open-Label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study.
